A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Evinacumab in Healthy Japanese and Caucasian Subjects
Phase of Trial: Phase I
Latest Information Update: 28 Jun 2018
At a glance
- Drugs Evinacumab (Primary) ; Evinacumab (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 21 Jun 2018 Status changed from active, no longer recruiting to completed.
- 26 Mar 2018 Planned End Date changed from 31 Jul 2018 to 13 Jun 2018.
- 26 Mar 2018 Planned primary completion date changed from 31 Jul 2018 to 13 Jun 2018.